J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e ● C o n t e n t s ● C u r r e n t e v e n t s ● R a n d o m a r t i c l e ● A b o u t W i k i p e d i a ● C o n t a c t u s ● D o n a t e
C o n t r i b u t e
● H e l p ● L e a r n t o e d i t ● C o m m u n i t y p o r t a l ● R e c e n t c h a n g e s ● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t ● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t ● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e ● C o n t r i b u t i o n s ● T a l k
( T o p )
1 R e f e r e n c e s
2 F u r t h e r r e a d i n g
3 E x t e r n a l l i n k s
T o g g l e t h e t a b l e o f c o n t e n t s
V o n o p r a z a n / a m o x i c i l l i n / c l a r i t h r o m y c i n
1 l a n g u a g e
● ف ا ر س ی
E d i t l i n k s
● A r t i c l e ● T a l k
E n g l i s h
● R e a d ● E d i t ● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d ● E d i t ● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e ● R e l a t e d c h a n g e s ● U p l o a d f i l e ● S p e c i a l p a g e s ● P e r m a n e n t l i n k ● P a g e i n f o r m a t i o n ● C i t e t h i s p a g e ● G e t s h o r t e n e d U R L ● D o w n l o a d Q R c o d e ● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F ● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
Vonoprazan/amoxicillin/clarithromycin , sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori ) infection.[1] [4] vonoprazan (as the fumarate), a potassium-competitive acid blocker ; amoxicillin , a beta-lactam antibiotic ; and clarithromycin , a macrolide antibiotic .[1] [4]
It was approved for medical use in Japan in 2016,[3] [1] [2] [5] [6] Food and Drug Administration (FDA) considers it to be a first-in-class medication .[7] [8]
References
[ edit ]
^ a b "Vonosap pack 400, Vonosap pack 800 and Vonopion pack (triple-drug blister packs containing Takecab tablet) Now Available for Helicobacter pylori[*] Eradication in Japan" . Takeda . 7 June 2016. Archived from the original on 10 May 2022. Retrieved 9 May 2022 .
^ a b Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S (July 2021). "Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis" . Advances in Therapy . 38 7 ): 3937–3947. doi :10.1007/s12325-021-01784-w . PMC 8280045 PMID 34091865 .
^ "FDA NDA approval" (PDF) . U.S. Food and Drug Administration (FDA) . Archived (PDF) from the original on 12 May 2022. Retrieved 12 May 2022 .
^ "Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) FDA Approval History" . Drugs.com .
^ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022" . U.S. Food and Drug Administration (FDA) . 10 January 2023. Retrieved 22 January 2023 .public domain .
^ New Drug Therapy Approvals 2022 (PDF) . U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024 .public domain .
Further reading
[ edit ]
Kajihara Y, Shimoyama T, Mizuki I (February 2017). "Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication". Scandinavian Journal of Gastroenterology . 52 2 ): 238–241. doi :10.1080/00365521.2016.1250157 . PMID 27806639 . S2CID 25801431 .
Nishida T, Tsujii Y, Okamoto A, Tomita R, Higaki Y, Osugi N, et al. (9 July 2019). "A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study". Digestion . 101 (5 ): 608–614. doi :10.1159/000501608 . PMID 31288235 . S2CID 195871882 .
Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, et al. (November 2020). "Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility". Journal of Gastroenterology . 55 11 ): 1054–1061. doi :10.1007/s00535-020-01723-6 . PMID 32930864 . S2CID 221674785 .
External links
[ edit ]
"Vonoprazan" . Drug Information Portal . U.S. National Library of Medicine.
"Amoxicillin" . Drug Information Portal . U.S. National Library of Medicine.
"Clarithromycin" . Drug Information Portal . U.S. National Library of Medicine.
t
e
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=Vonoprazan/amoxicillin/clarithromycin&oldid=1195535939 " C a t e g o r i e s : ● C o m b i n a t i o n a n t i b i o t i c s ● D r u g s a c t i n g o n t h e g a s t r o i n t e s t i n a l s y s t e m a n d m e t a b o l i s m ● P r o t o n - p u m p i n h i b i t o r s ● G a s t r o i n t e s t i n a l s y s t e m d r u g s t u b s H i d d e n c a t e g o r i e s : ● S o u r c e a t t r i b u t i o n ● A r t i c l e s w i t h s h o r t d e s c r i p t i o n ● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a ● U s e A m e r i c a n E n g l i s h f r o m M a y 2 0 2 2 ● A l l W i k i p e d i a a r t i c l e s w r i t t e n i n A m e r i c a n E n g l i s h ● U s e d m y d a t e s f r o m M a y 2 0 2 2 ● D r u g s w i t h n o n - s t a n d a r d l e g a l s t a t u s ● C h e m i c a l a r t i c l e s w i t h o u t C A S r e g i s t r y n u m b e r ● A r t i c l e s w i t h o u t E B I s o u r c e ● C h e m i c a l p a g e s w i t h o u t C h e m S p i d e r I D ● C h e m i c a l p a g e s w i t h o u t D r u g B a n k i d e n t i f i e r ● A r t i c l e s w i t h o u t I n C h I s o u r c e ● A r t i c l e s w i t h o u t U N I I s o u r c e ● A r t i c l e s c o n t a i n i n g u n v e r i f i e d c h e m i c a l i n f o b o x e s ● D r u g s t h a t a r e a c o m b i n a t i o n o f c h e m i c a l s ● A l l s t u b a r t i c l e s
● T h i s p a g e w a s l a s t e d i t e d o n 1 4 J a n u a r y 2 0 2 4 , a t 0 7 : 0 7 ( U T C ) . ● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n . ● P r i v a c y p o l i c y ● A b o u t W i k i p e d i a ● D i s c l a i m e r s ● C o n t a c t W i k i p e d i a ● C o d e o f C o n d u c t ● D e v e l o p e r s ● S t a t i s t i c s ● C o o k i e s t a t e m e n t ● M o b i l e v i e w
This article incorporates text from this source, which is in the public domain.
